NYSEAMERICAN:ASXC Asensus Surgical (ASXC) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free ASXC Stock Alerts $0.24 +0.00 (+1.38%) (As of 02:07 PM ET) Add Compare Share Share Today's Range$0.24▼$0.2550-Day Range N/A52-Week Range$0.20▼$0.69Volume479,184 shsAverage Volume1.49 million shsMarket Capitalization$65.90 millionP/E RatioN/ADividend YieldN/APrice Target$0.68 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Asensus Surgical alerts: Email Address Asensus Surgical MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside179.4% Upside$0.68 Price TargetShort InterestBearish6.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.19) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.27 out of 5 stars 3.0 Analyst's Opinion Consensus RatingAsensus Surgical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAsensus Surgical has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.19% of the float of Asensus Surgical has been sold short.Short Interest Ratio / Days to CoverAsensus Surgical has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Asensus Surgical has recently decreased by 6.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAsensus Surgical does not currently pay a dividend.Dividend GrowthAsensus Surgical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASXC. Previous Next 3.3 News and Social Media Coverage News SentimentAsensus Surgical has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Asensus Surgical this week, compared to 1 article on an average week.Search Interest4 people have searched for ASXC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Asensus Surgical to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Asensus Surgical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.87% of the stock of Asensus Surgical is held by insiders.Percentage Held by InstitutionsOnly 9.35% of the stock of Asensus Surgical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Asensus Surgical are expected to grow in the coming year, from ($0.19) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Asensus Surgical is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Asensus Surgical is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAsensus Surgical has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Asensus Surgical Stock (NYSEAMERICAN:ASXC)Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.Read More ASXC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASXC Stock News HeadlinesApril 29, 2024 | globenewswire.comAsensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery ProgramApril 27, 2024 | americanbankingnews.comAsensus Surgical (NYSEAMERICAN:ASXC) Shares Up 3.3%May 2, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 4, 2024 | markets.businessinsider.comWayfair To Rally Over 28%? Here Are 10 Top Analyst Forecasts For ThursdayApril 3, 2024 | bizjournals.comBillion-dollar firm moves to buy RTP outfit in need of capitalApril 3, 2024 | markets.businessinsider.comAsensus Surgical Agrees To Karl Storz's Acquisition Offer; Stock UpApril 3, 2024 | investorplace.comSmall Packages, Big Gains: 3 Penny Stocks to Buy as Q2 Kicks OffApril 3, 2024 | msn.comAsensus Surgical gains after Germany-based KARL STORZ announces buyout bidMay 2, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 3, 2024 | globenewswire.comAsensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KGMarch 26, 2024 | finance.yahoo.comASXC Oct 2024 0.500 putMarch 22, 2024 | benzinga.comAsensus Surgical Earnings PreviewMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Asensus Surgical Amidst Growth and Expansion ProspectsMarch 22, 2024 | msn.comAsensus Surgical, Inc. (AMEX:ASXC) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comASXC Stock Earnings: Asensus Surgical Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | benzinga.comRecap: Asensus Surgical Q4 EarningsMarch 21, 2024 | msn.comAsensus Surgical Non-GAAP EPS of -$0.07 misses by $0.02, revenue of $5.43M misses by $0.04MMarch 21, 2024 | markets.businessinsider.comAsensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023March 21, 2024 | globenewswire.comAsensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023March 21, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 21, 2024March 15, 2024 | globenewswire.comAsensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024March 7, 2024 | nz.finance.yahoo.comAsensus Surgical Inc (2TX.DU)February 28, 2024 | globenewswire.comAsensus Surgical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceFebruary 27, 2024 | globenewswire.comAsensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global HospitalsFebruary 22, 2024 | benzinga.comAsensus Surgical Stock (OTC:TRXDW) Dividends: History, Yield and DatesFebruary 6, 2024 | finance.yahoo.comDown -25.24% in 4 Weeks, Here's Why Asensus Surgical (ASXC) Looks Ripe for a TurnaroundJanuary 16, 2024 | finanznachrichten.deAsensus Surgical, Inc.: Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery ProgramSee More Headlines Receive ASXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/02/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolNYSEAMERICAN:ASXC CUSIPN/A CIKN/A Webwww.asensus.com Phone(919) 765-8400Fax919-765-8459Employees207Year FoundedN/APrice Target and Rating Average Stock Price Target$0.68 High Stock Price Target$1.00 Low Stock Price Target$0.35 Potential Upside/Downside+182.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,430,000.00 Net Margins-914.46% Pretax Margin-910.80% Return on Equity-135.94% Return on Assets-98.99% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.31 Sales & Book Value Annual Sales$8.58 million Price / Sales7.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book1.84Miscellaneous Outstanding Shares271,990,000Free Float264,180,000Market Cap$64.92 million OptionableNot Optionable Beta1.43 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Anthony Fernando (Age 52)President, CEO & Director Comp: $901.03kMr. Shameze Rampertab B.Sc. MBA (Age 57)CA, CPA, Executive VP & CFO Comp: $511.25kMr. Joshua B. Weingard (Age 51)Chief Legal Officer & Secretary Mr. Paul Ziegler Jr. (Age 50)J.D., Vice President of Sales Mr. Ethan LoiselleVice President of Global MarketingMs. Amanda OwensVice President of PeopleMr. Ravi KommineniHead of Global Quality & RegulatoryMr. Motti FrimerVice President of R&D, Digital Solutions and MD of Asensus SurgicalMore ExecutivesKey CompetitorsMonogram OrthopaedicsNASDAQ:MGRMPro-DexNASDAQ:PDEXenVVeno MedicalNASDAQ:NVNOBiostageOTCMKTS:BSTGSensus HealthcareNASDAQ:SRTSView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 15,800 shares on 2/2/2024Ownership: 0.000%William N Starling JrBought 18,134 shares on 12/14/2023Total: $5,077.52 ($0.28/share)View All Insider TransactionsView All Institutional Transactions ASXC Stock Analysis - Frequently Asked Questions Should I buy or sell Asensus Surgical stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Asensus Surgical in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ASXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASXC, but not buy additional shares or sell existing shares. View ASXC analyst ratings or view top-rated stocks. What is Asensus Surgical's stock price target for 2024? 2 brokers have issued 12 month price targets for Asensus Surgical's shares. Their ASXC share price targets range from $0.35 to $1.00. On average, they predict the company's stock price to reach $0.68 in the next year. This suggests a possible upside of 179.4% from the stock's current price. View analysts price targets for ASXC or view top-rated stocks among Wall Street analysts. Are investors shorting Asensus Surgical? Asensus Surgical saw a drop in short interest in April. As of April 15th, there was short interest totaling 16,510,000 shares, a drop of 7.0% from the March 31st total of 17,750,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is presently 10.4 days. Currently, 6.2% of the shares of the company are sold short. View Asensus Surgical's Short Interest. When is Asensus Surgical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ASXC earnings forecast. How were Asensus Surgical's earnings last quarter? Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) issued its earnings results on Thursday, March, 21st. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The business earned $5.43 million during the quarter. Asensus Surgical had a negative net margin of 914.46% and a negative trailing twelve-month return on equity of 135.94%. Who are Asensus Surgical's major shareholders? Asensus Surgical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrea Biffi, Anthony C J Fernando, David Bruce Milne, Elizabeth Kwo and William N Starling Jr. View institutional ownership trends. How do I buy shares of Asensus Surgical? Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:ASXC) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Asensus Surgical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.